1. Adjuvant therapy and prognosis in uterine carcinosarcoma
- Author
-
Chi-Yuan Chiang, Huei-Jean Huang, Wei-Yang Chang, Lan-Yan Yang, Ren-Chin Wu, Chun-Chieh Wang, Hsiu-Jung Tung, Angel Chao, and Chyong-Huey Lai
- Subjects
Adjuvant therapy ,Carcinosarcoma ,Chemoradiation ,Overall survival ,Prognostic factors ,Medicine (General) ,R5-920 - Abstract
Purpose: To investigate the prognostic factors and impact of adjuvant treatment on uterine carcinosarcoma (UCS). Methods: A retrospective review of UCS patients treated between 2005 and 2019 was conducted. International Federation of Gynecology and Obstetrics (FIGO) 2009 staging system was used. Multivariate stepwise Cox proportional hazard regression models were used to identify the independent predictors of overall survival (OS) and progression-free survival (PFS). Results: A total of 138 patients were eligible for descriptive analysis. Excluding 12 patients without surgery, 126 patients with adequate clinicopathologic data were included for prognostic analysis. The median follow-up for survivors was 51.8 months. 5-year OS and PFS rates for FIGO stage I, II, III, IV were 64.5% and 51.8%, 60.8% and 57.7%, 47.7% and 45.9%, 5.1% and 4.1%, respectively. By multivariate analysis, six models each for PFS and OS were formulated including highly correlated variables alternatively. Adjuvant chemoradiation was consistently selected as an independent prognostic factor for OS (hazard ratio [HR] 0.10–0.22, all p
- Published
- 2021
- Full Text
- View/download PDF